RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic and liver-disease research. Published trials have reported reductions in liver fat and, in a separate biopsy-based study, improvement in one measure of steatohepatitis. However, improvement in liver inflammation and improvement in scarring are different outcomes. This review explains three publications and the important limits of their findings, including the fibrosis endpoint that was not met in the 24-week IMPACT analysis. [1–3]
WHAT THESE LIVER STUDIES MEASURE
Metabolic dysfunction-associated steatotic liver disease, or MASLD, involves excess liver fat in a metabolic-disease setting. MASH refers to the inflammatory form, while fibrosis describes scarring. A magnetic resonance scan can estimate liver fat; a biopsy examines tissue features. Those measurements answer related but different questions. [1,3]
Pemvidutide's dual receptor activity provides a rationale for investigating several metabolic outcomes together. That rationale is not proof of each proposed benefit. The relevant evidence comes from the endpoints actually measured with a defined clinical study product.
THE INITIAL 12-WEEK TRIAL
Harrison and colleagues randomized 94 participants with MASLD to three pemvidutide groups or placebo. At twelve weeks, the active groups had relative reductions in liver fat ranging from approximately 47% to 69%, compared with approximately 4% for placebo. Liver fat was assessed using magnetic resonance imaging. [1]
These are relative reductions in the measured liver-fat value, not percentage-point losses of total body fat. The study also reported changes in body weight and selected liver-related markers. No severe or serious adverse events were reported in this small, short trial, which cannot exclude uncommon or longer-term risks. [1]
THE EXTENSION FOLLOWED A SUBSET OF PARTICIPANTS
Browne and colleagues reported an additional twelve weeks of treatment in 64 participants who entered an extension of the earlier trial. They continued their original assignment, producing a total observation period of 24 weeks. Relative liver-fat reductions in the active groups ranged from approximately 56% to 76%, compared with 14% for placebo. [2]
This publication adds follow-up information but should not be counted as a completely independent replication in a new population. Extension participants are a subset of the original cohort. The study's imaging-based findings also do not, by themselves, establish reversal of biopsy-confirmed fibrosis or prevention of future liver complications.
IMPACT SEPARATED MASH RESOLUTION FROM FIBROSIS
The phase 2b IMPACT trial randomized 212 adults with biopsy-confirmed MASH and stage F2 or F3 fibrosis. Noureddin and colleagues reported two primary outcomes at 24 weeks. MASH resolution without worsening fibrosis occurred in approximately 58% and 52% of the two pemvidutide groups, compared with 20% of the placebo group. [3]
The separate endpoint of fibrosis improvement without worsening MASH did not show a statistically significant advantage over placebo. Adverse events were reported more often in the active groups, although most were mild or moderate and treatment discontinuations due to adverse events were uncommon. Altimmune funded the trial. [3]
Both endpoint results are needed for an accurate account. The favorable MASH finding supports further research, while the fibrosis result prevents describing this analysis as demonstrated scar reversal. Twenty-four-week tissue findings also do not establish a reduction in liver failure or mortality.
HOW TO INTERPRET THE OVERALL RECORD
These studies provide clinical evidence about specific investigational formulations and selected patient populations. They do not establish that a separately supplied laboratory product has the same identity, quality or effects. Findings from an imaging study, an extension cohort and a biopsy-based trial should remain distinguishable.
For readers evaluating pemvidutide research, the most useful questions concern which endpoint changed, whether the comparison was statistically convincing and how long participants were observed. A positive result in one domain does not settle every efficacy or safety question, and it does not support personal use of research material.
REFERENCES
1. Harrison SA, Browne SK, Suschak JJ, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. Journal of Hepatology. 2025;82:7–17.
https://doi.org/10.1016/j.jhep.2024.07.006
2. Browne SK, Suschak JJ, Tomah S, et al. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP Reports. 2025;7:101483.
https://doi.org/10.1016/j.jhepr.2025.101483
3. Noureddin M, Harrison SA, Loomba R, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. The Lancet. 2025;406:2644–2655.
https://doi.org/10.1016/S0140-6736(25)02114-2